Skip to main content
. 2018 May 29;10(7):e8307. doi: 10.15252/emmm.201708307

Figure 1. AICAR but not metformin prevents IFNγ/TNFα‐induced myotube atrophy.

Figure 1

  • A
    Western blotting for phospho‐Thr172‐AMPK (pAMPK), total AMPK, phospho‐Ser79‐ACC (pACC), and total ACC 24h after treatment. Quantification represents the pAMPK/AMPK and pACC/ACC ratios relative to the non‐treated (NT) control.
  • B
    Phase contrast images of fibers 72 h after treatment. Scale bars represent 0.25 mm.
  • C
    Immunofluorescence staining for myoglobin and myosin heavy chain (MyHC) 48 h after treatment. Scale bars represent 50 μm. Quantification represents the average myotube width.
  • D, E
    RT–qPCR analysis of the mRNA levels of MyoD (D) and myogenin (E) 24 h after treatment relative to the NT control.
Data information: All quantifications are of three independent experiments (n = 3) and error bars represent standard error of the mean (SEM). Significance between means was first determined using ANOVA. Significance P‐values were calculated using Fisher's LSD. *< 0.05; **P < 0.01 from NT controls; †† P < 0.01 from IFNγ/TNFα‐treated controls.Source data are available online for this figure.